Edward Faber
Hematology & Oncology · Cincinnati, OHNPI 1326163981
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $59,204 of the $72,418 with a category attached, or 81.8%. 27 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 29.6% of the total. Reporting peaked in 2022 at $18,554 and has fallen 98.3% since, to $313 in 2025. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $778.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$21K
- Bristol Myers Squibb$9K
- Johnson & Johnson$8K
- Gilead$5K
- Sanofi$5K
- Karyopharm Therapeutics Inc.$3K
- plus $21K from 21 others
Across 487 payments — averaging $4505.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.1M
- Genentech, Inc.$279K
- Janssen Research & Development, LLC$251K
- AbbVie$223K
- Incyte Corporation$163K
- Sanofi$46K
- plus $89K from 4 others
What the payments were for
- Consulting fees$59,20482%
- Speaking & faculty fees$8,56112%
- Travel & lodging$3,4705%
- Food & beverage$1,0621%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $21,406 |
| Bristol Myers Squibb | 13 | $9,434 |
| Johnson & Johnson(2 entities) | 15 | $8,135 |
| Gilead | 5 | $4,694 |
| Sanofi | 2 | $4,536 |
| Karyopharm Therapeutics Inc. | 3 | $3,023 |
| AstraZeneca | 1 | $2,800 |
| Adaptive Biotechnologies Corporation | 3 | $2,700 |
| Janssen Scientific Affairs, LLC | 6 | $2,338 |
| GSK | 4 | $2,203 |
| Blueprint Medicines Corporation | 1 | $1,980 |
| CTI Biopharma Corp. | 1 | $1,725 |
| Janssen Global Services, LLC | 2 | $1,635 |
| AbbVie | 1 | $1,375 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,375 |
| Epizyme, Inc. | 2 | $1,262 |
| Amgen | 3 | $1,124 |
| Aurobindo Pharma USA, Inc. | 3 | $287 |
| Legend Biotech USA Inc. | 2 | $143 |
| Lilly USA, LLC | 1 | $100 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $16 |
| Incyte Corporation | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,418 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 54 | $770,672 |
| PomalystPomalidomide | 31 | $744,189 |
| RevlimidLenalidomide | 26 | $462,306 |
| VyndamaxTafamidis | 14 | $328,347 |
| NinlaroIxazomib Citrate | 16 | $234,155 |
| SprycelDasatinib | 20 | $200,938 |
| EliquisApixaban | 33 | $25,811 |
| Acyclovir | 113 | $1,685 |
| Dexamethasone | 48 | $820 |
| ValacyclovirValacyclovir Hcl | 15 | $726 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 28 | $289 |
| Gabapentin | 15 | $181 |
| Prochlorperazine Maleate | 12 | $175 |
| Montelukast Sodium | 17 | $133 |
| Levofloxacin | 11 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $21,406 | $945,12751 claims |
| Bristol Myers SquibbRevlimid | $9,434 | $462,30626 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $1,375 | $234,15516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cincinnati
- David WaterhouseCincinnati$1.3M
- Mark AndolinaCincinnati$402K
- James EssellCincinnati$214K
- Akash MukherjeeCincinnati$132K
- Davendra SohalCincinnati$112K
- Alexander StarodubCincinnati$72K
- Brittaney Belle GordonCincinnati$53K
- Soumit BasuCincinnati$46K
- Trisha Wise-DraperCincinnati$44K
- Emily CurranCincinnati$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.